Download original image
Fig. 1.
Treatment and outcome of patients.
a)
Enocitabine, idarubicin, intrathecal cytarabine;
b)
cytarabine, idarubicin, mitoxantrone.Abbreviations: AML, acute myeloid leukemia; CR, complete remission; DOD, died of disease; HSCT, hematopoietic stem cell transplant; MRD, matched related donor; MUD, matched unrelated donor; N, number; NED, no evidence of disease; TRM, treatment-related mortality.
Blood Res 2020;55:217~224
https://doi.org/10.5045/br.2020.2020127
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by
INFOrang Co., Ltd